Marcel A M Beijk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6216258/publications.pdf

Version: 2024-02-01

758635 610482 38 586 12 24 citations h-index g-index papers 39 39 39 893 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Genousâ,,¢ endothelial progenitor cell capturing stent vs. the Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. European Heart Journal, 2010, 31, 1055-1064.	1.0	106
2	Multiple Biomarkers at Admission Significantly Improve the Prediction of Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2011, 57, 29-36.	1.2	91
3	MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability. Open Heart, 2020, 7, e001223.	0.9	45
4	Genousâ,,¢ endothelial progenitor cell-capturing stent system: a novel stent technology. Expert Review of Medical Devices, 2009, 6, 365-375.	1.4	40
5	XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. Expert Review of Medical Devices, 2007, 4, 11-21.	1.4	38
6	Twoâ€year followâ€up of the genousâ,,¢ endothelial progenitor cell capturing stent versus the taxus liberté stent in patients with <i>De Novo</i> coronary artery lesions with a highâ€risk of restenosis. Catheterization and Cardiovascular Interventions, 2011, 78, 189-195.	0.7	38
7	p27 ^{kip1} –838C>A Single Nucleotide Polymorphism Is Associated With Restenosis Risk After Coronary Stenting and Modulates p27 ^{kip1} Promoter Activity. Circulation, 2009, 120, 669-676.	1.6	27
8	Pulmonary vascular imaging characteristics after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2020, 39, 248-256.	0.3	16
9	Design and rationale of the TRI-stent Adjudication Study (TRIAS) Program. American Heart Journal, 2009, 158, 527-532.e1.	1.2	14
10	Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities. Journal of Clinical Medicine, 2022, 11, 1361.	1.0	14
11	Evaluation of clinical outcomes after C <scp>OMBO</scp> stent treatment in patients presenting with acute coronary syndrome. Catheterization and Cardiovascular Interventions, 2017, 90, E31-E37.	0.7	13
12	Two-year clinical outcomes of patients treated with the dual-therapy stent in a 1000 patient all-comers registry. Open Heart, 2017, 4, e000634.	0.9	13
13	Oneâ€year clinical outcome in an unselected patient population treated with the Genousâ,,¢ endothelial progenitor cell capturing stent. Catheterization and Cardiovascular Interventions, 2011, 77, 809-817.	0.7	12
14	Clinical outcomes after percutaneous or surgical revascularisation of unprotected left main coronary artery-related acute myocardial infarction: a single-centre experience. Heart, 2013, 99, 690-699.	1.2	12
15	Clinical outcomes after percutaneous coronary intervention with the COMBO stent versus Resolute Integrity and PROMUS Element stents: a propensity-matched analysis. EuroIntervention, 2017, 13, 1202-1209.	1.4	11
16	Three-Year Clinical Follow-Up of an Unselected Patient Population Treated with the Genous Endothelial Progenitor Cell Capturing Stent. Journal of Interventional Cardiology, 2011, 24, 442-449.	0.5	10
17	Differences in cardiovascular risk factors and clinical outcomes between Western European and Southeast Asian patients treated with the Genous Bio-engineered R stent. Coronary Artery Disease, 2012, 23, 271-277.	0.3	10
18	One-year clinical outcome after provisional T-stenting for bifurcation lesions with the endothelial progenitor cell capturing stent compared with the bare-metal stent. Atherosclerosis, 2010, 213, 525-531.	0.4	9

#	Article	IF	Citations
19	Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention. Pharmacogenetics and Genomics, 2010, 20, 544-552.	0.7	8
20	Threeâ€year clinical outcomes after dualâ€therapy COMBO stent placement: Insights from the REMEDEE registry. Catheterization and Cardiovascular Interventions, 2019, 94, 342-347.	0.7	8
21	A retrospective analysis of consecutive patients undergoing nonurgent percutaneous coronary intervention comparing bare metal stents with drug-eluting stents using the National Institute for Clinical Excellence criteria. Coronary Artery Disease, 2011, 22, 32-39.	0.3	7
22	Applying the National Institute for Clinical Excellence criteria to patients treated with the Genousâ,,¢ Bio-engineered R stentâ,,¢: a sub-study of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits) Tj ETC)q0 0.\$ rg	BT /Øverlock 1
23	Significant intimal hyperplasia regression between 6 and 18 months following Genousâ,,¢ endothelial progenitor cell capturing stent placement. International Journal of Cardiology, 2011, 147, 289-291.	0.8	6
24	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. International Journal of Cardiovascular Imaging, 2019, 35, 1189-1198.	0.7	6
25	Longâ€term followâ€up after nonurgent percutaneous coronary intervention in unprotected left main coronary arteries. Catheterization and Cardiovascular Interventions, 2010, 75, 1026-1036.	0.7	4
26	Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drugâ€eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy. Catheterization and Cardiovascular Interventions, 2020, 95, 89-96.	0.7	4
27	Clinical outcomes after bareâ€metal stenting in diabetic patients with lesions carrying a low risk of restenosis. Catheterization and Cardiovascular Interventions, 2013, 81, 26-33.	0.7	3
28	Early discontinuation of dual antiplatelet therapy in patients treated with the bio-engineered pro-healing sirolimus-eluting (COMBO) stent. Cardiovascular Revascularization Medicine, 2018, 19, 373-375.	0.3	3
29	Long-Term Performance of the COMBO Dual-Therapy Stent: Results from the REMEDEE Registry. Cardiovascular Revascularization Medicine, 2020, 21, 567-570.	0.3	3
30	A case report of myocardial infarction with non-obstructive coronary artery disease: Graves' disease-induced coronary artery vasospasm. European Heart Journal - Case Reports, 2020, 4, 1-5.	0.3	3
31	Clinical course of sinus node dysfunction after thoracoscopic surgery for atrial fibrillation—analysis of the Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery (AFACT) study. Journal of Interventional Cardiac Electrophysiology, 2021, 60, 185-193.	0.6	2
32	Respirationâ€related variations in Pd/Pa ratio and fractional flow reserve in resting conditions and during intravenous adenosine administration. Catheterization and Cardiovascular Interventions, 2021, , .	0.7	2
33	Cangrelor Use in Routine Practice: A Two-Center Experience. Journal of Clinical Medicine, 2021, 10, 2829.	1.0	1
34	Predicting the outcomes of pulmonary hypertension is aÂbreathtaking task. Netherlands Heart Journal, 2020, 28, 623-624.	0.3	0
35	Left internal mammary artery injury and subsequent hypovolemic shock due to a hemothorax after subxiphoid pericardiocentesis in a postoperative cardiac surgery patient. Clinical Case Reports (discontinued), 2021, 9, 2360-2364.	0.2	0
36	Implementation of CT Coronary Angiography as an Alternative to Invasive Coronary Angiography in the Diagnostic Work-Up of Non-Coronary Cardiac Surgery, Cardiomyopathy, Heart Failure and Ventricular Arrhythmias. Journal of Clinical Medicine, 2021, 10, 2374.	1.0	0

#	Article	IF	CITATIONS
37	The relationship between the number of preprocedural circulating endothelial progenitor cells and angiographic restenosis following coronary artery stent placement. Heart Asia, 2011, 3, 60-5.	1.1	O
38	Transradial access in chronic anticoagulated patients: One step closer to a "radial-first―strategy in all patients. International Journal of Cardiology, 2022, 348, 45-46.	0.8	0